NCT01406600

Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: Female
• Age: 21 Years – 44 Years
• Healthy volunteers: Not accepted

Summary

Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte maturation triggering in assisted reproductive technology (ART).Recombinant hCG has been investigated about its safety and efficacy comparing with urinary hCG, but still the optimal dose of rhCG is questionable. From former studies, there only have been proven that high dose of hCG can make ovarian hyperstimulation syndrome (OHSS) in usual condition. On the other hand, we hypothesize that high dose of hCG may improve oocyte maturity in poor responders who cannot easily provoke OHSS. Hence, this study will assess the comparative efficacy and safety of 250mcg and 500mcg of rhCG in ART treatment cycle.

Detailed description

Randomized prospective clinical study that compare the two doses of rhCG (250mcg vs. 500mcg).

Conditions

• in Vitro Fertilization
• Poor Responder

Interventions

Type	Name	Description
DRUG	recombinant hCG (Ovidrel®)	Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-11-01
• Completion: 2013-12-01
• First posted: 2011-08-01
• Last updated: 2013-04-12

Locations

1 site across 1 country: South Korea